Effects of the APOEɛ4 Allele on the Relationship Between Tau and Amyloid-β in Early- and Late-Onset Alzheimer's Disease.

BACKGROUND Little is known regarding the differential effects of the apolipoprotein E (APOE) ɛ4 on the regional topography of amyloid and tau in patients with both early-onset (EOAD) and late-onset Alzheimer's disease (LOAD). OBJECTIVE To compare the distribution and association of tau, amyloid, and cortical thickness among groups classified by the presence of APOEɛ4 allele and onset age. METHODS A total of 165 participants including 54 EOAD patients (29 ɛ4-; 25 ɛ4+), 45 LOAD patients (21 ɛ4-; 24 ɛ4+), and 66 age-matched controls underwent 3T MRI, 18F-THK5351 (THK) and 18F-flutemetamol (FLUTE) PET scans, APOE genotyping, and neuropsychological tests. Data for voxel-wise and standardized uptake values from PET scans were analyzed in the context of APOE and age at onset. RESULTS EOAD ɛ4- patients showed greater THK retention in the association cortices, whereas their EOAD ɛ4+ counterparts had more retention in medial temporal areas. THK topography of LOAD ɛ4+ was similar to EOAD ɛ4 + . THK correlated positively with FLUTE and conversely with mean cortical thickness, being lowest in EOAD ɛ4-, highest in LOAD ɛ4-, and modest in ɛ4+ groups. Even in the APOEɛ4+ groups, THK tended to correlate with FLUTE and mean cortical thickness in the inferior parietal region in EOAD and in the medial temporal region in LOAD. LOAD ɛ4- manifested with prevalent small vessel disease markers and the lowest correlation between THK retention and cognition. CONCLUSION Our observations suggest the differential effects of the APOEɛ4 on the relationship between tau and amyloid in EOAD and LOAD.

[1]  D. Yang,et al.  The Seoul Neuropsychological Screening Battery (SNSB) for Comprehensive Neuropsychological Assessment , 2023, Dementia and neurocognitive disorders.

[2]  V. Villemagne,et al.  Imaging of Reactive Astrogliosis by Positron Emission Tomography , 2022, Frontiers in Neuroscience.

[3]  G. Frisoni,et al.  Clinical validity of increased cortical binding of tau ligands of the THK family and PBB3 on PET as biomarkers for Alzheimer’s disease in the context of a structured 5-phase development framework , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[4]  W. Jagust,et al.  Association of APOE4 and Clinical Variability in Alzheimer Disease With the Pattern of Tau- and Amyloid-PET , 2020, Neurology.

[5]  Sheina Emrani,et al.  APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer’s disease: a systematic review , 2020, Alzheimer's Research & Therapy.

[6]  Hanna Cho,et al.  Effect of APOE ε4 genotype on amyloid-β and tau accumulation in Alzheimer’s disease , 2020, Alzheimer's research & therapy.

[7]  S. Gauthier,et al.  APOEε4 potentiates the relationship between amyloid-β and tau pathologies , 2020, Molecular Psychiatry.

[8]  Muhammad Naveed Iqbal Qureshi,et al.  Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β. , 2019, JAMA neurology.

[9]  Paul E. Gilbert,et al.  APOE interacts with tau PET to influence memory independently of amyloid PET in older adults without dementia , 2019, Alzheimer's & dementia : the journal of the Alzheimer's Association.

[10]  D. Holtzman,et al.  Alzheimer Disease: An Update on Pathobiology and Treatment Strategies , 2019, Cell.

[11]  T. Südhof,et al.  Differential Signaling Mediated by ApoE2, ApoE3, and ApoE4 in Human Neurons Parallels Alzheimer's Disease Risk , 2019, The Journal of Neuroscience.

[12]  K. Bötzel,et al.  PET Imaging of Astrogliosis and Tau Facilitates Diagnosis of Parkinsonian Syndromes , 2019, Front. Aging Neurosci..

[13]  Alan C. Evans,et al.  Topographical Heterogeneity of Alzheimer’s Disease Based on MR Imaging, Tau PET, and Amyloid PET , 2019, Front. Aging Neurosci..

[14]  J. Kessler,et al.  Neuronal apolipoprotein E4 increases cell death and phosphorylated tau release in alzheimer disease , 2019, Annals of neurology.

[15]  William J. Jagust,et al.  Effect of Off-Target Binding on 18F-Flortaucipir Variability in Healthy Controls Across the Life Span , 2019, The Journal of Nuclear Medicine.

[16]  Michael D. Greicius,et al.  A Quarter Century of APOE and Alzheimer’s Disease: Progress to Date and the Path Forward , 2019, Neuron.

[17]  K. Bötzel,et al.  [18F]-THK5351 PET Correlates with Topology and Symptom Severity in Progressive Supranuclear Palsy , 2018, Front. Aging Neurosci..

[18]  D. Na,et al.  Tau positron emission tomography using [18F]THK5351 and cerebral glucose hypometabolism in Alzheimer's disease , 2017, Neurobiology of Aging.

[19]  D. Na,et al.  [18F]-THK5351 PET Imaging in Patients With Semantic Variant Primary Progressive Aphasia , 2017, Alzheimer disease and associated disorders.

[20]  Daniel R. Schonhaut,et al.  Local and distant relationships between amyloid, tau and neurodegeneration in Alzheimer's Disease , 2017, NeuroImage: Clinical.

[21]  H. Arai,et al.  Correlations of 18F-THK5351 PET with Postmortem Burden of Tau and Astrogliosis in Alzheimer Disease , 2017, The Journal of Nuclear Medicine.

[22]  Rik Ossenkoppele,et al.  Distinct 18F‐AV‐1451 tau PET retention patterns in early‐ and late‐onset Alzheimer's disease , 2017, Brain : a journal of neurology.

[23]  Hanna Cho,et al.  Excessive tau accumulation in the parieto-occipital cortex characterizes early-onset Alzheimer's disease , 2017, Neurobiology of Aging.

[24]  S. Gauthier,et al.  Monoamine oxidase B inhibitor, selegiline, reduces 18F-THK5351 uptake in the human brain , 2017, Alzheimer's Research & Therapy.

[25]  C. Rowe,et al.  Tau imaging with [18F]THK‐5351 in progressive supranuclear palsy , 2017, European journal of neurology.

[26]  W. Jagust,et al.  Dynamic PET Measures of Tau Accumulation in Cognitively Normal Older Adults and Alzheimer’s Disease Patients Measured Using [18F] THK-5351 , 2016, PloS one.

[27]  Ciprian Catana,et al.  Different partial volume correction methods lead to different conclusions: An 18F-FDG-PET study of aging , 2016, NeuroImage.

[28]  D. Bennett,et al.  Association of APOE with tau-tangle pathology with and without β-amyloid , 2016, Neurobiology of Aging.

[29]  P. Scheltens,et al.  Early onset APOE E4-negative Alzheimer’s disease patients show faster cognitive decline on non-memory domains , 2015, European Neuropsychopharmacology.

[30]  Sang Won Seo,et al.  Anatomical heterogeneity of Alzheimer disease , 2014, Neurology.

[31]  Lennart Thurfjell,et al.  Automated Quantification of 18F-Flutemetamol PET Activity for Categorizing Scans as Negative or Positive for Brain Amyloid: Concordance with Visual Image Reads , 2014, The Journal of Nuclear Medicine.

[32]  Kazuhiko Yanai,et al.  Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. , 2014, Brain : a journal of neurology.

[33]  Bruce R. Rosen,et al.  Cortical surface-based analysis reduces bias and variance in kinetic modeling of brain PET data , 2014, NeuroImage.

[34]  R. Petersen,et al.  Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study , 2011, The Lancet Neurology.

[35]  B. Hyman,et al.  Neuropathological alterations in Alzheimer disease. , 2011, Cold Spring Harbor perspectives in medicine.

[36]  Nick C Fox,et al.  Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE ɛ4 allele , 2011, The Lancet Neurology.

[37]  D. Holtzman,et al.  The Role of Apolipoprotein E in Alzheimer's Disease , 2009, Neuron.

[38]  Steven Warach,et al.  Cerebral Microbleeds : A Field Guide to their Detection and Interpretation , 2012 .

[39]  Ramon Casanova,et al.  Biological parametric mapping: A statistical toolbox for multimodality brain image analysis , 2007, NeuroImage.

[40]  D. Neary,et al.  Apolipoprotein E ε4 Allele Frequency and Age at Onset of Alzheimer’s Disease , 2006, Dementia and Geriatric Cognitive Disorders.

[41]  K. Ishii,et al.  The effect of APOE &egr;4 allele on cerebral glucose metabolism in AD is a function of age at onset , 2002, Neurology.

[42]  K. Welsh-Bohmer,et al.  APOE genotype predicts when — not whether — one is predisposed to develop Alzheimer disease , 1998, Nature Genetics.

[43]  B T Hyman,et al.  Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease , 1996, Annals of neurology.

[44]  S. Gauthier,et al.  Apolipoprotein E polymorphism and Alzheimer's disease , 1993, The Lancet.

[45]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[46]  Jong Min Lee,et al.  The Impact of APOE ɛ4 in Alzheimer's Disease Differs According to Age. , 2018, Journal of Alzheimer's disease : JAD.

[47]  Sang Won Seo,et al.  Amyloid deposition in early onset versus late onset Alzheimer's disease. , 2013, Journal of Alzheimer's disease : JAD.

[48]  A. Roses,et al.  Apolipoprotein E and Alzheimer's disease. , 1996, Annual review of neuroscience.

[49]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .